Myeloproliferative Neoplasms clinical trials at UC Irvine
1 research study open to new patients
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.
Orange, California and other locations